Intermittent adjuvant chemo-immunotherapy after resection of non-small cell lung cancer with multilevel mediastinal lymph node metastasis

Oncology Reports

Volumn 7, Issue 3, 2000, Pages 545-549

  Suzuki, Makoto ^a   Kimura, Hideki ^a   Iwai, Naomichi ^a   Fujisawa, Takehiko ^a  

^a CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemo immunotherapy; Interferon ; Interleukin 2; Lymphokine activated killer cells; Multilevel mediastinal lymph node metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MITOMYCIN; VINDESINE;

ADJUVANT CHEMOTHERAPY; ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; VINDESINE;

EID: 0034185270     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.3.545     Document Type: Article

References (27)

1. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323: 940-945, 1990.
2. Marino P, Preatoni A and Cantoni A: Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer. Cancer 76: 593-601, 1995.
3. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, et al: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342: 19-21, 1993.
4. Dillman RO, Herndon J, Seagren SL, Eaton WL and Green MR: Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88: 1210-1215, 1996.
5. Watanabe Y, Shimizu J, Oda M, Hayashi Y, Watanabe S, et al: Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg 51: 253-261, 1991.
6. Ishida T, Tateishi M, Kaneko S and Sugimachi K: Surgical treatment of patients with non-small cell lung cancer and mediastinal lymph node involvement. J Surg Oncol 43: 161-166, 1990.
7. Vansteenkiste JF, de Leyn PR, Deneffe GJ, Stapaert G, Nackaerts KL, et al: Lung Cancer Group. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thoracic Surg 63: 1441-1450, 1997.
8. Mountain CF: Surgery for stage IIIa-N2 non-small cell lung cancer. Cancer 73: 2589-2598, 1997.
9. Sawyer TE, Bonner JA, Gould PM, Foote RL, Deschamps C, et al: The impact of surgical adjuvant thoracic radiation therapy for patients with non-small cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 80: 1399-1408, 1997.
10. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT III, et al: Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stage IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group Phase II Study 8805. J Clin Oncol 13: 1880-1892, 1995.
11. Klaveren RJ, Festen J, Otten HJAM, Cox AL, Graaf R and Lacquet LK: Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg 56: 300-304, 1993.
12. Goldstraw P, Mannam GC, Kaplan DK, Michail P and Shields TW: Surgical management of non-small cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 107: 19-28, 1994.
13. Shepherd FA: Induction chemotherapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 55: 1585-1592, 1993.
14. Rusch VW, Albain KS, Crowley JJ, Rice TW, Lonchyna V, et al: Surgical resection of stage IIIA and stage IIIB non-small cell lung cancer after concurrent induction chemoradiotherapy A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 105: 97-106, 1993.
15. Martini N, Kris MG, Flehinger BJ, Gralla RJ, Bains MS, et al: Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 55: 1365-1374, 1993.
16. Pujol JL, Gibney DJ, Su JQ, Maksymiuk AW and Jett JR: Immune response induced in small cell lung cancer by maintenance therapy with interferon γ. J Natl Cancer Inst 85: 1844-1850, 1993.
17. Jett JR, Maksymiuk AW, Su JQ, Mailliard JA, Krook JE, et al: Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer. J Clin Oncol 12: 2321-2326, 1994.
18. Kimura H and Yamaguchi Y: A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or non-curative resection of primary lung carcinoma. Cancer 80: 42-49, 1997.
19. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492, 1985.
20. Mitchell MS, Kempf RA, Harel W, Shau H, Boswell WD, et al: Effectiveness and tolerability of low-dose cyclophosphamide and low dose-intravenous interleukin-2 in disseminated melanoma. J Clin Oncol 6: 409-424, 1988.
21. Kedar E, Ben-Aziz R and Shiloni E: Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells. Isr J Med Sci 24: 494-504, 1988.
22. Hosokawa M, Sawamura Y, Morikage T, Okada F, Xu ZY, et al: Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cancer Immunol Immunother 26: 250-256, 1988.
23. 2+ independent T cell-mediated cytotoxicity. J Exp Med 177: 195-200, 1993.
24. + T cell-mediated cytotoxicity. J Immunol 152: 1127-1133, 1994.
25. Hanabuchi S, Koyanagi M, Kawasaki A, Shinohara N, Matsuzawa A, et al: Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity. Proc Natl Acad Sci USA 91: 4930-4934, 1994.
26. + cytotoxic T cells. Proc Natl Acad Sci USA 91: 4185-4189, 1994.
27. + T cell clones use perform- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol 158: 2756-2761, 1997.